Sinovac Biotech, Ltd. (NASDAQ:SVA) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on Friday.

Shares of Sinovac Biotech (NASDAQ SVA) opened at 6.75 on Friday. The stock’s market capitalization is $384.53 million. The stock has a 50 day moving average price of $5.39 and a 200 day moving average price of $5.65. Sinovac Biotech has a 12 month low of $4.60 and a 12 month high of $6.92.

ILLEGAL ACTIVITY NOTICE: “Sinovac Biotech, Ltd. (NASDAQ:SVA) Rating Increased to Hold at ValuEngine” was originally published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/07/01/sinovac-biotech-ltd-nasdaqsva-rating-increased-to-hold-at-valuengine.html.

Several large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC raised its stake in Sinovac Biotech by 10.1% in the first quarter. Renaissance Technologies LLC now owns 1,679,490 shares of the biopharmaceutical company’s stock valued at $9,623,000 after buying an additional 154,690 shares in the last quarter. Morgan Stanley raised its stake in Sinovac Biotech by 86,309.9% in the first quarter. Morgan Stanley now owns 2,721,912 shares of the biopharmaceutical company’s stock valued at $15,597,000 after buying an additional 2,718,762 shares in the last quarter. Geode Capital Management LLC raised its stake in Sinovac Biotech by 45.3% in the first quarter. Geode Capital Management LLC now owns 39,476 shares of the biopharmaceutical company’s stock valued at $225,000 after buying an additional 12,306 shares in the last quarter. Verity Asset Management Inc. bought a new stake in Sinovac Biotech during the first quarter valued at $158,000. Finally, Spark Investment Management LLC raised its stake in Sinovac Biotech by 62.5% in the first quarter. Spark Investment Management LLC now owns 54,600 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 21,000 shares in the last quarter. 37.97% of the stock is owned by institutional investors and hedge funds.

Sinovac Biotech Company Profile

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Sinovac Biotech Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.